Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Morphine | 14 | 2017 | 657 | 2.760 |
Why?
|
| Nucleus Accumbens | 9 | 2020 | 366 | 2.290 |
Why?
|
| Extinction, Psychological | 10 | 2023 | 376 | 2.070 |
Why?
|
| Narcotics | 6 | 2017 | 343 | 1.390 |
Why?
|
| Proto-Oncogene Proteins c-fos | 7 | 2014 | 575 | 1.350 |
Why?
|
| Substance Withdrawal Syndrome | 14 | 2014 | 632 | 1.140 |
Why?
|
| Fear | 6 | 2023 | 1440 | 0.980 |
Why?
|
| Dendrites | 4 | 2017 | 485 | 0.970 |
Why?
|
| GABA Agonists | 5 | 2009 | 111 | 0.920 |
Why?
|
| Conditioning, Classical | 5 | 2014 | 366 | 0.910 |
Why?
|
| Baclofen | 5 | 2009 | 129 | 0.900 |
Why?
|
| Ventral Tegmental Area | 4 | 2020 | 142 | 0.880 |
Why?
|
| Arousal | 4 | 2022 | 1165 | 0.870 |
Why?
|
| Reward | 6 | 2023 | 941 | 0.780 |
Why?
|
| Tobacco Use Disorder | 5 | 2014 | 688 | 0.740 |
Why?
|
| Motor Activity | 13 | 2011 | 2714 | 0.670 |
Why?
|
| Analgesics, Opioid | 5 | 2023 | 3674 | 0.670 |
Why?
|
| Receptors, GABA-B | 3 | 2003 | 68 | 0.670 |
Why?
|
| Amygdala | 4 | 2023 | 1315 | 0.630 |
Why?
|
| Smoking | 9 | 2014 | 8987 | 0.630 |
Why?
|
| Caffeine | 10 | 1999 | 699 | 0.560 |
Why?
|
| Homing Behavior | 1 | 2015 | 5 | 0.540 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2022 | 4266 | 0.530 |
Why?
|
| Learning | 3 | 2014 | 1713 | 0.500 |
Why?
|
| Schizophrenic Psychology | 5 | 2012 | 1678 | 0.490 |
Why?
|
| Benzazepines | 1 | 2017 | 326 | 0.490 |
Why?
|
| Dopamine Agonists | 1 | 2017 | 355 | 0.480 |
Why?
|
| Alprazolam | 4 | 2000 | 98 | 0.460 |
Why?
|
| Receptors, Purinergic P1 | 3 | 1999 | 109 | 0.460 |
Why?
|
| Sleep | 3 | 2022 | 4623 | 0.420 |
Why?
|
| Brain Concussion | 1 | 2023 | 1320 | 0.410 |
Why?
|
| Naltrexone | 2 | 2007 | 307 | 0.410 |
Why?
|
| Neuronal Plasticity | 3 | 2020 | 1422 | 0.400 |
Why?
|
| Veterans | 3 | 2022 | 2519 | 0.380 |
Why?
|
| Valproic Acid | 1 | 2013 | 445 | 0.370 |
Why?
|
| Smoking Cessation | 5 | 2014 | 2071 | 0.360 |
Why?
|
| Neostriatum | 1 | 2011 | 250 | 0.360 |
Why?
|
| Adenosine | 6 | 2008 | 825 | 0.350 |
Why?
|
| Nootropic Agents | 1 | 2011 | 160 | 0.350 |
Why?
|
| Corpus Striatum | 5 | 2005 | 1221 | 0.340 |
Why?
|
| Limbic System | 3 | 2008 | 426 | 0.340 |
Why?
|
| Mice, Inbred C57BL | 12 | 2023 | 21827 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2017 | 10943 | 0.340 |
Why?
|
| Adenosine A1 Receptor Agonists | 1 | 2008 | 12 | 0.340 |
Why?
|
| Schizophrenia | 7 | 2012 | 6882 | 0.340 |
Why?
|
| Receptors, Purinergic | 3 | 1993 | 66 | 0.320 |
Why?
|
| Purinergic P1 Receptor Agonists | 2 | 1999 | 38 | 0.320 |
Why?
|
| Autonomic Nervous System | 1 | 2013 | 671 | 0.320 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 789 | 0.310 |
Why?
|
| Purinergic P1 Receptor Antagonists | 2 | 1999 | 45 | 0.310 |
Why?
|
| Prefrontal Cortex | 3 | 2023 | 2147 | 0.310 |
Why?
|
| Morphine Dependence | 2 | 1998 | 31 | 0.280 |
Why?
|
| Anti-Anxiety Agents | 2 | 2000 | 390 | 0.280 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2010 | 604 | 0.280 |
Why?
|
| Articulation Disorders | 1 | 2005 | 14 | 0.280 |
Why?
|
| Schizophrenic Language | 1 | 2005 | 69 | 0.270 |
Why?
|
| GTP-Binding Proteins | 3 | 1999 | 970 | 0.270 |
Why?
|
| Speech Production Measurement | 1 | 2005 | 98 | 0.270 |
Why?
|
| Mice | 28 | 2023 | 81183 | 0.260 |
Why?
|
| Depressive Disorder | 2 | 2021 | 3748 | 0.260 |
Why?
|
| Animals | 36 | 2023 | 168757 | 0.260 |
Why?
|
| Speech Acoustics | 1 | 2005 | 151 | 0.250 |
Why?
|
| Heart Rate | 3 | 2013 | 4091 | 0.250 |
Why?
|
| Conditioning, Operant | 2 | 2012 | 313 | 0.230 |
Why?
|
| Cerebral Cortex | 6 | 2008 | 5708 | 0.230 |
Why?
|
| Delusions | 1 | 2006 | 300 | 0.230 |
Why?
|
| Panic Disorder | 2 | 2000 | 616 | 0.220 |
Why?
|
| Nicotine | 2 | 2008 | 681 | 0.220 |
Why?
|
| Antipsychotic Agents | 4 | 2005 | 3057 | 0.210 |
Why?
|
| Haloperidol | 2 | 2004 | 397 | 0.210 |
Why?
|
| Phenethylamines | 2 | 1999 | 96 | 0.210 |
Why?
|
| Alcoholism | 2 | 2004 | 1906 | 0.210 |
Why?
|
| Oxycodone | 1 | 2023 | 153 | 0.200 |
Why?
|
| Culture | 1 | 2006 | 633 | 0.200 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 491 | 0.200 |
Why?
|
| Awareness | 1 | 2006 | 640 | 0.200 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2004 | 514 | 0.200 |
Why?
|
| Male | 47 | 2023 | 350118 | 0.190 |
Why?
|
| Cocaine-Related Disorders | 1 | 2004 | 460 | 0.190 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2006 | 6038 | 0.180 |
Why?
|
| Behavior, Addictive | 5 | 2012 | 462 | 0.180 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 1999 | 87 | 0.180 |
Why?
|
| Pirenzepine | 1 | 1999 | 115 | 0.170 |
Why?
|
| Adenosine Kinase | 1 | 1998 | 12 | 0.170 |
Why?
|
| Pituitary-Adrenal System | 1 | 2022 | 553 | 0.170 |
Why?
|
| Behavior, Animal | 5 | 2012 | 1881 | 0.160 |
Why?
|
| Central Nervous System Depressants | 1 | 1999 | 167 | 0.160 |
Why?
|
| Space Perception | 2 | 2014 | 475 | 0.160 |
Why?
|
| Brain Injuries | 1 | 2010 | 2025 | 0.160 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2022 | 703 | 0.160 |
Why?
|
| Neurons | 4 | 2020 | 9338 | 0.150 |
Why?
|
| Telencephalon | 1 | 1998 | 142 | 0.150 |
Why?
|
| Spatial Behavior | 1 | 2017 | 90 | 0.140 |
Why?
|
| Cocaine | 2 | 2012 | 1007 | 0.140 |
Why?
|
| Dopamine | 2 | 2020 | 1591 | 0.140 |
Why?
|
| Receptors, GABA-A | 3 | 1990 | 627 | 0.140 |
Why?
|
| Psychomotor Performance | 2 | 2012 | 1901 | 0.140 |
Why?
|
| Motivation | 2 | 2010 | 1971 | 0.140 |
Why?
|
| Psychotic Disorders | 3 | 2012 | 3046 | 0.140 |
Why?
|
| Benzodiazepines | 3 | 2004 | 1101 | 0.140 |
Why?
|
| Brain | 12 | 2017 | 26385 | 0.140 |
Why?
|
| Anxiety | 1 | 2010 | 4297 | 0.130 |
Why?
|
| Substance-Related Disorders | 2 | 2010 | 4258 | 0.130 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2017 | 291 | 0.130 |
Why?
|
| Mice, Inbred Strains | 5 | 1998 | 1827 | 0.120 |
Why?
|
| Depression | 1 | 2014 | 7766 | 0.120 |
Why?
|
| Receptors, AMPA | 2 | 2012 | 331 | 0.120 |
Why?
|
| Butyric Acid | 1 | 2013 | 55 | 0.120 |
Why?
|
| Xanthines | 4 | 1999 | 121 | 0.120 |
Why?
|
| GABA-B Receptor Agonists | 2 | 2003 | 15 | 0.110 |
Why?
|
| Electroshock | 1 | 2013 | 122 | 0.110 |
Why?
|
| Ethanol | 1 | 1999 | 1342 | 0.110 |
Why?
|
| Cues | 3 | 2012 | 873 | 0.110 |
Why?
|
| Dendritic Spines | 1 | 2014 | 233 | 0.100 |
Why?
|
| Signal Detection, Psychological | 1 | 2012 | 85 | 0.100 |
Why?
|
| Administration, Cutaneous | 3 | 2012 | 711 | 0.100 |
Why?
|
| Hypothalamus | 1 | 1997 | 1063 | 0.100 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2011 | 23 | 0.100 |
Why?
|
| Half-Life | 3 | 2000 | 661 | 0.100 |
Why?
|
| GABA Agents | 1 | 2011 | 42 | 0.100 |
Why?
|
| Adrenergic Agents | 1 | 2011 | 70 | 0.090 |
Why?
|
| Neural Pathways | 1 | 2002 | 2972 | 0.090 |
Why?
|
| Cholinergic Agents | 1 | 2011 | 93 | 0.090 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2012 | 312 | 0.090 |
Why?
|
| Drug Interactions | 3 | 2003 | 1460 | 0.090 |
Why?
|
| Carbon Monoxide | 3 | 2011 | 531 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2015 | 6365 | 0.090 |
Why?
|
| Breath Tests | 2 | 2011 | 280 | 0.090 |
Why?
|
| Dopamine Agents | 1 | 2011 | 189 | 0.090 |
Why?
|
| Comorbidity | 3 | 2017 | 10388 | 0.080 |
Why?
|
| Bupropion | 1 | 2011 | 303 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 1997 | 1148 | 0.080 |
Why?
|
| Theophylline | 1 | 2008 | 132 | 0.080 |
Why?
|
| Combat Disorders | 1 | 2010 | 302 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 11366 | 0.080 |
Why?
|
| Humans | 25 | 2023 | 744343 | 0.080 |
Why?
|
| Bipolar Disorder | 1 | 2004 | 5027 | 0.070 |
Why?
|
| Adult | 15 | 2023 | 214055 | 0.070 |
Why?
|
| Tablets | 1 | 2007 | 145 | 0.070 |
Why?
|
| Capsules | 1 | 2007 | 196 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 1992 | 1572 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2003 | 1959 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 2 | 1999 | 425 | 0.070 |
Why?
|
| Middle Aged | 10 | 2014 | 213383 | 0.070 |
Why?
|
| Reaction Time | 1 | 2012 | 2097 | 0.060 |
Why?
|
| Behavior Therapy | 1 | 2011 | 865 | 0.060 |
Why?
|
| Nicotinic Agonists | 1 | 2007 | 271 | 0.060 |
Why?
|
| Phonetics | 1 | 2005 | 206 | 0.060 |
Why?
|
| GABA-B Receptor Antagonists | 1 | 2003 | 13 | 0.060 |
Why?
|
| Models, Animal | 1 | 2011 | 2171 | 0.060 |
Why?
|
| Time Factors | 4 | 2013 | 40075 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 1997 | 5021 | 0.060 |
Why?
|
| GABA Antagonists | 1 | 2003 | 128 | 0.060 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 153 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2000 | 2029 | 0.060 |
Why?
|
| Female | 16 | 2023 | 380194 | 0.060 |
Why?
|
| Estrous Cycle | 1 | 2023 | 73 | 0.060 |
Why?
|
| Radioligand Assay | 2 | 1994 | 374 | 0.060 |
Why?
|
| Double-Blind Method | 4 | 2011 | 12026 | 0.050 |
Why?
|
| Psychopathology | 1 | 2006 | 409 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2006 | 8324 | 0.050 |
Why?
|
| Narcotic Antagonists | 1 | 2007 | 562 | 0.050 |
Why?
|
| Risperidone | 1 | 2004 | 383 | 0.050 |
Why?
|
| Demography | 1 | 2007 | 1656 | 0.050 |
Why?
|
| Prosencephalon | 1 | 2003 | 303 | 0.050 |
Why?
|
| Military Personnel | 1 | 2010 | 1133 | 0.050 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2004 | 503 | 0.050 |
Why?
|
| Memory | 1 | 2011 | 2174 | 0.050 |
Why?
|
| Quality of Life | 1 | 2022 | 12804 | 0.050 |
Why?
|
| Psychometrics | 2 | 2010 | 3002 | 0.050 |
Why?
|
| Long-Term Care | 1 | 2004 | 607 | 0.050 |
Why?
|
| Fluoxetine | 1 | 2004 | 749 | 0.050 |
Why?
|
| Marijuana Abuse | 1 | 2004 | 403 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 1997 | 7880 | 0.050 |
Why?
|
| Thioinosine | 1 | 1999 | 4 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2004 | 1472 | 0.040 |
Why?
|
| Flumazenil | 2 | 1990 | 84 | 0.040 |
Why?
|
| Taste | 1 | 2000 | 176 | 0.040 |
Why?
|
| 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 1 | 1998 | 7 | 0.040 |
Why?
|
| Deoxyadenosines | 1 | 1998 | 27 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2006 | 2373 | 0.040 |
Why?
|
| Receptor, Adenosine A2A | 1 | 1999 | 124 | 0.040 |
Why?
|
| Drug Tolerance | 2 | 1998 | 376 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2007 | 3913 | 0.040 |
Why?
|
| Opioid-Related Disorders | 1 | 2014 | 2065 | 0.040 |
Why?
|
| Feedback | 1 | 2002 | 795 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2012 | 8436 | 0.040 |
Why?
|
| Nucleoside Transport Proteins | 1 | 1997 | 7 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2004 | 1530 | 0.040 |
Why?
|
| Neural Inhibition | 1 | 2002 | 602 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 3647 | 0.040 |
Why?
|
| Gyrus Cinguli | 1 | 2003 | 1091 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2004 | 3002 | 0.030 |
Why?
|
| Rats | 3 | 2023 | 24260 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 4933 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2002 | 1121 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2002 | 1178 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2010 | 4245 | 0.030 |
Why?
|
| Aged | 4 | 2014 | 163280 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2010 | 23403 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 6489 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2012 | 21746 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2007 | 8554 | 0.030 |
Why?
|
| Pharmaceutical Vehicles | 1 | 1993 | 59 | 0.030 |
Why?
|
| Electroencephalography | 2 | 2000 | 6150 | 0.030 |
Why?
|
| Nerve Net | 1 | 2005 | 2174 | 0.030 |
Why?
|
| Affect | 1 | 2021 | 1476 | 0.030 |
Why?
|
| Area Under Curve | 1 | 1997 | 1654 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1994 | 1157 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1999 | 1609 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1993 | 156 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2023 | 8301 | 0.030 |
Why?
|
| Brain Stem | 1 | 1997 | 846 | 0.030 |
Why?
|
| Lorazepam | 1 | 1992 | 145 | 0.030 |
Why?
|
| Self Administration | 1 | 2012 | 385 | 0.020 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2011 | 295 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 1990 | 326 | 0.020 |
Why?
|
| Cotinine | 1 | 2011 | 206 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 12959 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 12072 | 0.020 |
Why?
|
| Cerebellum | 1 | 1997 | 1488 | 0.020 |
Why?
|
| Stereotyped Behavior | 1 | 1990 | 136 | 0.020 |
Why?
|
| Attention | 1 | 2000 | 2400 | 0.020 |
Why?
|
| Emotions | 1 | 2021 | 2661 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 57776 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2011 | 421 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 2274 | 0.020 |
Why?
|
| Binding Sites | 1 | 1997 | 6114 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2012 | 1901 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 1992 | 647 | 0.020 |
Why?
|
| Up-Regulation | 1 | 1997 | 4217 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2000 | 3966 | 0.020 |
Why?
|
| Body Weight | 1 | 1998 | 4669 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 3798 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 19905 | 0.020 |
Why?
|
| Kinetics | 2 | 1992 | 6473 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 29786 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 1990 | 981 | 0.020 |
Why?
|
| Logistic Models | 1 | 1998 | 13408 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 39050 | 0.010 |
Why?
|
| United States | 1 | 2010 | 69872 | 0.010 |
Why?
|
| Age Factors | 1 | 1998 | 18370 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 1992 | 2838 | 0.010 |
Why?
|
| Guanylyl Imidodiphosphate | 1 | 1998 | 36 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 8642 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1998 | 683 | 0.010 |
Why?
|
| Models, Biological | 1 | 1993 | 9583 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1998 | 2327 | 0.010 |
Why?
|
| Sulfur Radioisotopes | 1 | 1989 | 116 | 0.010 |
Why?
|
| Muscimol | 1 | 1989 | 69 | 0.010 |
Why?
|
| Synaptosomes | 1 | 1989 | 115 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 15226 | 0.010 |
Why?
|
| Chlorides | 1 | 1989 | 667 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2012 | 63114 | 0.000 |
Why?
|
| Ion Channels | 1 | 1989 | 1056 | 0.000 |
Why?
|
| Young Adult | 1 | 2010 | 56430 | 0.000 |
Why?
|
| Ligands | 1 | 1989 | 3282 | 0.000 |
Why?
|
| Adolescent | 1 | 2005 | 85781 | 0.000 |
Why?
|
Concepts
(258)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(13)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_